The global urinalysis market is expected to grow at a compound annual growth rate (CAGR) of 8.1% from 2022 to 2027 to reach $5.7 billion, according to a new report from MarketsandMarkets Research. Key factors driving this growth include an increased focus on disease screening by governments, a high prevalence of lifestyle diseases like diabetes and kidney disease, and greater efforts to promote awareness about these conditions.
The largest product segment in the urinalysis market consists of consumables, including items like test strips, reagents, and disposables. This is due to rising investments in developing new diagnostic products, improving provider awareness regarding rapid diagnostic technologies, and an increased need for rapid disease diagnosis.
In terms of test type, pregnancy and fertility tests make up the dominant segment. This is attributed to advancements in diagnostic product technology. By application, disease screening makes up the majority of the market, largely thanks to an aging population and age-related diseases, emerging economies providing growth opportunities, and greater adoption of point-of-care diagnosis including urinalysis for fast and convenient results.
Diagnostic laboratories are the leading end-user segment, accounting for the greatest market share. Supporting factors include increased age-related diseases, more frequent use of point-of-care analyzers, and favorable regulatory guidelines and reimbursement scenarios in developed regions like North America and Europe.
Geographically, North America holds the largest share of the global urinalysis market. Growth in this region is driven by escalating rates of diseases such as diabetes and UTIs, supportive government health policies, and substantial investment in the development and approval of new diagnostic tests for preventive care.
The urinalysis market does face some headwinds restrainting faster growth. The availability of low-cost refurbished urine analyzers in developing countries has hampered expansion opportunities. And more stringent regulatory requirements for in vitro diagnostic products in the U.S. and Europe pose challenges as well.
But market conditions still present lucrative opportunities, especially across emerging economies. Elements like large patient populations, improving healthcare infrastructure, rising disposable incomes, and increasing medical tourism will facilitate upgrading laboratory capabilities in these countries.
Some recent key developments help showcase innovative product launches and partnerships designed to tap into growth opportunities in the global urinalysis space:
- In September 2022, Sysmex Corporation introduced its UF-1500 fully automated urine particle analyzer for urine sediment testing.
- In February 2021, Thermo Fisher Scientific and Shenzhen Mindray Bio-Medical Electronics signed a deal to provide automated urine analyzers to toxicology labs.
- In August 2020, an exclusive agreement was announced between Sysmex America and Siemens Healthineers.
Major players operating in the global urinalysis ecosystem include Siemens Healthineers, F. Hoffmann-La Roche, Cardinal Health, Abbott Laboratories, Danaher Corporation, Sysmex Corporation, Quidel Corporation, Becton Dickinson, Bio-Rad Laboratories, Shenzhen Mindray, and more. These companies will likely continue pursuing product innovation, partnerships, and geographic expansion to widen their market shares going forward.
